Blue BG Sub banner
Blue BG Sub banner

AD &
the Patient Journey

Decades before the onset of mild cognitive impairment (MCI), amyloid beta (Aβ) begins accumulating in the brain, contributing to neurodegeneration. In the amyloid cascade model of AD, the continuous accumulation of Aβ underlies the irreversible, ongoing nature of neurodegeneration within AD1.

Learning Zone

Review self-guided learning decks on topics, including the underlying pathophysiology of the disease and etiological hypotheses, risk factors for AD, the AD continuum, the evolving patient journey, and much more.

Practical Zone

Review self-guided learning decks with a more practical focus of diagnosing Alzheimer’s disease that will include case studies to frame key diagnostic steps — more case studies coming soon!

Visual and Video Zone

Review visual flashcards for quick learning topics on AD or hear experts present case studies of a patient’s journey through an early diagnosis, some of the challenges that can impact early diagnosis and operational insights on how to try to overcome them.

Video Lectures

Challenges and solutions for a timely
diagnosis of AD

Viewing time: 8 minutes 40 seconds

Speaker: Dr. Malaz Boustani

Watch this presentation to understand the benefits of an early diagnosis and the challenges primary care providers face in achieving this. As part of this presentation, Dr. Boustani summarizes unmet needs in the current clinical care pathway for AD and possible solutions on the horizon to address these.


Patient and caregiver barriers to a timely
diagnosis of AD

Viewing time: 8 minutes 30 seconds

Speaker: Dr. Malaz Boustani

In this presentation, Dr. Boustani discusses the factors that influence an individual’s acceptance of dementia screening and the negative impact of societal stigma on early diagnosis of AD and defines the key changes needed to address these challenges and prepare healthcare systems for the timely detection of AD.


Expert Insights

Clinical practice considerations for fluid
biomarkers in AD

Viewing time: 21 minutes

Speaker: Dr Suzanne Schindler

In this interview, Dr Suzanne Schindler addresses questions on how fluid biomarkers of AD are being used in the clinic. She discusses the clinical use of biomarkers in the context of a typical diagnostic pathway and navigates important topics including their diagnostic accuracy, ethical considerations, and healthcare infrastructural requirements to support their implementation.




  1. Hampel H, et al. Mol Psychiatry. 2021;26(10):5481–5503.